Skip to main content

Table 2 Application of MCC950 for treating different pain conditions

From: The NLRP3 inflammasome: an emerging therapeutic target for chronic pain

Pain condition

Species

Administration route

Administration dosage

Dosage regimen

References

Oxaliplatin-induced CIPN

SD rats

i.t.

5 μmol/day

Once daily for 25 consecutive days

[30]

CPIP

SD rats

i.t.

30 μg/rat

Once daily for 7 consecutive days

[31]

RR-EAE

C57 mice

i.g.

50 mg/kg

Once daily for 21 consecutive days

[32]

FSL1-induced inflammatory pain

C57 mice

i.p.

10 mg/kg

Single dose

[33]

NTG-induced migraine

C57 mice

i.p.

10 mg/kg

Once daily for 11 consecutive days

[34]

EAP

NOD/LtJ non-obese diabetic (NOD) mice

i.p.

10 mg/kg

Once a day or every other day for a total of 7 treatments

[35]

BCP

SD rats

i.p.

5 mg/kg; 10 mg/kg

For acute treatment: single dose

[15]

 

5 mg/kg; 10 mg/kg

For chronic treatment: once daily for 5 consecutive days

Morphine- or fentanyl-induced hyperalgesia

Wistar rats

i.p.

5 mg/kg

Once daily for 7 consecutive days

[24]